All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Both all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ) have proven to be very effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but they had not been used jointly in an integrated treatment protocol for remission induction or maintenance among newly diagnosed APL patients. In this study, 61 newly diagnosed APL subjects were randomized into three treatment groups, namely by ATRA, As 2 O 3 , and the combination of the two drugs. CR was determined by hematological analysis, tumor burden was examined with real-time quantitative RT-PCR of the PML-RAR α (promyelocytic leukemia - retinoic acid receptor α) fusion transcripts, and side effects were evaluated by means of clinical examinations. Mechanisms possibly involved were also investigated with cellular and molecular biology methods. Although CR rates in three groups were all high (≥90%), the time to achieve CR differed significantly, with that of the combination group being the shortest one. Earlier recovery of platelet count was also found in this group. The disease burden as reflected by fold change of PML-RARα transcripts at CR decreased more significantly in combined therapy as compared with ATRA or As 2 O 3 mono-therapy ( P < 0.01). This difference persisted after consolidation ( P < 0.05). Importantly, all 20 cases in the combination group remained in CR whereas 7 of 37 cases treated with mono-therapy relapsed ( P < 0.05) after a follow-up of 8–30 months (median: 18 months). Synergism of ATRA and As 2 O 3 on apoptosis and degradation of PML-RARα oncoprotein might provide a plausible explanation for superior efficacy of combinative therapy in clinic. In conclusion, the ATRA/As 2 O 3 combination for remission/maintenance therapy of APL brings much better results than either of the two drugs used alone in terms of the quality of CR and the status of the disease-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Self-citationPathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
Jaffe, E. S. (2003) · Cited by 2,141
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Self-citationDifferentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Self-citationCastaigne, S., Chomienne, C., Daniel, M., Ballerini, P., Berger, R., Fenaux, P., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1704.1704 · Cited by 1,184
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062
Cited by
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Natural Products in Cancer Therapy: Past, Present and Future
Huang, M., Lu, J.-J., & Ding, J. (2021) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00293-7 · Cited by 648
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Chen, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2943 · Cited by 488
Self-citationHu, J., Liu, Y.-F., Wu, C.-F., Xu, F., Shen, Z.-X., Zhu, Y.-M., Li, J.-M., Tang, W., Zhao, W.-L., Wu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813280106 · Cited by 425
Self-citationRetinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Dilda, P. J., & Hogg, P. J. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.05.001 · Cited by 389
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6130 · Cited by 376
Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1533 · Cited by 356
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
Self-citationMathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R. V., Srivastava, V. M., Srivastava, A., & Chandy, M. (2006) · Blood · doi:10.1182/blood-2005-08-3532 · Cited by 343
Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410746 · Cited by 329
What has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y.-K., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 328
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
de Thé, H., Pandolfi, P. P., & Chen, Z. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.002 · Cited by 297
Self-citationAbaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736686 · Cited by 286
Acute promyelocytic leukemia: where did we start, where are we now, and the future
Coombs, C. C., Tavakkoli, M., & Tallman, M. S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.25 · Cited by 280
Arsenic trioxide — An old drug rediscovered
Emadi, A., & Gore, S. D. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.04.001 · Cited by 279
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein
Isakson, P., Bjørås, M., Bøe, S. O., & Simonsen, A. (2010) · Blood · doi:10.1182/blood-2010-01-261040 · Cited by 268
Zheng, P.-Z., Wang, K.-K., Zhang, Q.-Y., Huang, Q.-H., Du, Y.-Z., Zhang, Q.-H., Xiao, D.-K., Shen, S.-H., Imbeaud, S., Eveno, E., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502825102 · Cited by 256
Self-citationModern Approaches to Treating Acute Promyelocytic Leukemia
Sanz, M. A., & Lo-Coco, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1067 · Cited by 220
Martinez-Outschoorn, U. E., Goldberg, A. F., Lin, Z., Ko, Y.-H., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17780 · Cited by 174
Evidence of Hemoglobin Binding to Arsenic as a Basis for the Accumulation of Arsenic in Rat Blood
Lu, M., Wang, H., Li, X.-F., Lu, X., Cullen, W. R., Arnold, L. L., Cohen, S. M., & Le, X. C. (2004) · Chemical Research in Toxicology · doi:10.1021/tx049756s · Cited by 167
Biological Responses to Arsenic Compounds
Platanias, L. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r900003200 · Cited by 164
The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?
Ablain, J., Nasr, R., Bazarbachi, A., & de Thé, H. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0087 · Cited by 44
Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha
Tarrade, A., Bastien, J., Bruck, N., Bauer, A., Gianni, M., & Rochette-Egly, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208402 · Cited by 23
“Finally, As2O3 also induced the disappearance of RARa in several cell lines (data not shown) such as the SqCC/Y1 and NB4 cell lines (Gianni et al., 1998; Zhu et al., 2001; Shen et al., 2004).”
BackgroundInfluentialJain, P., Kantarjian, H., Estey, E., Pierce, S., Cortes, J., Lopez-Berestein, G., & Ravandi, F. (2014) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.08.004 · Cited by 15
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)
Damery, E., Solimando, D. A., & Waddell, J. A. (2016) · Hospital Pharmacy · doi:10.1310/hpj5108-628 · Cited by 7
Metadata
- Authors
- Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., de Thé, H., Wang, Z.-Y., Chen, S.-J., & Chen, Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-03-24
- Volume
- 101
- Issue
- 15
- Pages
- 5328-5335
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2046705094
- Cited by
- 583
- References
- 47
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.